LAKE OSWEGO, Ore., Oct. 26, 2011 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that data from the Phase 2 clinical trial of NeuVax™ will be presented at the 26th Annual Meeting of the Society for the Immunotherapy of Cancer. The event is being held November 4-6, 2011 at the Bethesda North Marriott Hotel & Conference Center in North Bethesda, Maryland.
